High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS

Proteasome inhibitors (PIs) such as bortezomib constitute an important part of the modern standard therapy for multiple myeloma (MM). In this study, we set out to assess whether proteasome concentration and chymotrypsin-like (ChT-L) activity could serve as potential biomarkers defining the likelihoo...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ann Hematol
Hlavní autoři: Romaniuk, Wioletta, Bolkun, Lukasz, Kalita, Joanna, Galar, Marzenna, Bernatowicz, Malgorzata, Ostrowska, Halina, Kloczko, Janusz
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Berlin Heidelberg 2018
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6097751/
https://ncbi.nlm.nih.gov/pubmed/29946907
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-018-3393-7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky